← Human Trials & Peer-Reviewed Studies
Copper intrauterine device increases vaginal concentrations of inflammatory anaerobes and depletes lactobacilli compared to hormonal options in a randomized trial.
Plain-language guide to PMID 36717556 (2023): randomized controlled trial of Copper (Supplement) in 218 women.
Key Facts
- PMID
- 36717556
- Journal
- Nature communications
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Brown BP et al. (20 authors)
- DOI
- 10.1038/s41467-023-36002-4
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
However, there remains a lack of rigorous data regarding the effects of contraceptive options on vaginal bacteria and inflammation.
Among 218 women enrolled into a substudy of the ECHO Trial (NCT02550067), the researchers evaluate the effect of injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG), and a copper intrauterine device (Cu-IUD) on the vaginal environment after one and six consecutive months of use, using 16S rRNA gene sequencing and multiplex cytokine assays.
Who Took Part
The study group was 218 women.
PubMed indexes the participants as adults, women only.
How the Study Was Run
The design is described as randomized.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
Among 218 women enrolled into a substudy of the ECHO Trial (NCT02550067), the researchers evaluate the effect of injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG), and a copper intrauterine device (Cu-IUD) on the vaginal environment after one and six consecutive months of use, using 16S rRNA gene sequencing and multiplex cytokine assays.
Primary endpoints include incident BV occurrence, bacterial diversity, and bacterial and cytokine concentrations.
PubMed files the paper under topics including Intrauterine Devices, Copper, Medroxyprogesterone Acetate, Lactobacillus, RNA, Ribosomal, 16S, Bacteria, Anaerobic and Contraceptive Agents.
What This Means in Plain Language
The paper is a randomized study of Copper (Supplement) in 218 women.
The publication is from 2023 (Nature communications), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.